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Pathways to diagnosis of non-small cell lung cancer: a
descriptive cohort study
Stuart Purdie1, Nicola Creighton 1, Kahren Maree White1, Deborah Baker1, Dan Ewald2,3, Chee Khoon Lee4,5, Alison Lyon6,
Johnathan Man7, David Michail7, Alexis Andrew Miller8,9, Lawrence Tan6, David Currow1 and Jane M. Young10,11
Little has been published on the diagnostic and referral pathway for lung cancer in Australia. This study set out to quantify general
practitioner (GP) and lung specialist attendance and diagnostic imaging in the lead-up to a diagnosis of non-small cell lung cancer
(NSCLC) and identify common pathways to diagnosis in New South Wales (NSW), Australia. We used linked health data for
participants of the 45 and Up Study (a NSW population-based cohort study) diagnosed with NSCLC between 2006 and 2012. Our
main outcome measures were GP and specialist attendances, X-rays and computed tomography (CT) scans of the chest and lung
cancer-related hospital admissions. Among our study cohort (N= 894), 60% (n= 536) had ≥4 GP attendances in the 3 months prior
to diagnosis of NSCLC, 56% (n= 505) had GP-ordered imaging (chest X-ray or CT scan), 39% (N= 349) attended a respiratory
physician and 11% (N= 102) attended a cardiothoracic surgeon. The two most common pathways to diagnosis, accounting for one
in three people, included GP and lung specialist (respiratory physician or cardiothoracic surgeon) involvement. Overall, 25% of
people (n= 223) had an emergency hospital admission. For 14% of people (N= 129), an emergency hospital admission was the
only event identified on the pathway to diagnosis. We found little effect of remoteness of residence on access to services. This
study identified a substantial proportion of people with NSCLC being diagnosed in an emergency setting. Further research is
needed to establish whether there were barriers to the timely diagnosis of these cases.
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INTRODUCTION
Lung cancer kills more people than any other cancer in Australia.1
Five-year survival has improved since the 1980s but remains poor
(16% for 2009–2013).1 Evidence-based treatment is critical to
further improve outcomes for people with lung cancer. Numerous
studies examining treatment pathways for people with lung
cancer in Australia have identified gaps in optimal treatment
delivery.2–8 While there are studies that have focussed on the
pathway from the point of specialist referral and treatment
planning onwards4-9, there are fewer studies on the primary care,
diagnostic and referral pathways to the point of specialist
contact.10,11 To our knowledge, no Australian study has examined
the use of diagnostic imaging and specialist referral in the lead-up
to lung cancer diagnosis.
Although lung cancer is one of the most common cancers in
Australia (43 new cases per 100,000 people per year1), it will be
encountered rarely by an individual general practitioner (GP) and
diagnosis can be challenging. The early symptoms of lung cancer,
such as weight loss, a new or changing cough, shortness of breath
and chest pain, are often non-specific. The absence of symptoms
for many people until disease is advanced makes early diagnosis
challenging. Haemoptysis, a “red flag” symptom, only occurs in
around one fifth of people presenting with lung cancer.12,13 Most
people require imaging beyond a simple chest X-ray to confirm
the diagnosis of lung cancer.14
People with suspected lung cancer should be referred for
specialist assessment, including obtaining a tissue diagnosis and
oversight by a multi-disciplinary team charged with developing a
consensus-based treatment plan.14,15 New South Wales (NSW)
studies found that a lung cancer multidisciplinary team (MDT)
increased the use of treatment,16 while reduced access to
specialist care may account for poorer outcomes for people in
rural settings.3,17
In this study, we aimed to quantify the use and pattern of GP
attendances, specialist attendances and diagnostic imaging in a
community/outpatient setting in the lead-up to diagnosis and
identify common diagnostic pathways of NSW residents with non-
small cell lung cancer (NSCLC). A secondary aim was to measure
health service use by remoteness of residence.
RESULTS
A total of 1235 people were diagnosed with NSCLC between
enrolment into the 45 and Up Study (February 2006) and 31
December 2012. There were 894 people in the study cohort
(Table 1) after excluding cases notified only by death certificate
(n= 34), people with another cancer case diagnosed between
2000 and 2012 (n= 251) and cases with an estimated diagnosis
date (n= 56).
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Use of health services in the lead-up to diagnosis
The rate of GP attendance was <1 per person 15 months prior to
NSCLC diagnosis, increasing gradually from 6 months prior to
diagnosis (Fig. 1) before reaching a peak of just under two per
person in the month of diagnosis. Rapid increases in the number
of chest X-rays, chest computed tomography (CT) scans and lung
specialist attendances in a community setting coincided with the
rapid increase in GP attendances from 2 months before diagnosis.
In the 3 months to diagnosis, 93% of people attended a GP,
with 60% attending ≥4 times; 39% attended a respiratory
physician; 11% attended a cardiothoracic surgeon; while <10%
attended a medical or radiation oncologist, general physician or
general surgeon (Table 2). Just under half (46%) of people had a
diagnostic procedure (bronchoscopy or biopsy) recorded. Just
over half had a chest X-ray (53%) or chest CT scan (59%) in a
community setting, with most imaging ordered by a GP. Around
40% of people had both a chest X-ray and CT scan and almost a
third of people did not have a record of either (Table 3). We could
not determine how many people saw a lung specialist or had
chest imaging during an inpatient admission.
Although there were some differences in distribution of number
of GP attendances, the median and interquartile range of GP
attendances were the same for all remoteness areas (median: 4,
interquartile range: 3–6). Specialist attendances were similar
across remoteness areas. Respiratory physician attendance was
not substantially higher (χ2(2)= 1.98, P= 0.37) for those living in
major cities (41%), compared with inner regional (37%) and outer
regional/remote areas (35%).
Pathways to diagnosis
The two most common pathways to diagnosis, accounting for
30% of people, included GP-ordered imaging and lung specialist
attendance without an emergency hospital admission (Table 4).
Pathways including a lung specialist attendance (n= 405, 45%)
had a higher proportion of cases with a histopathologically
confirmed diagnosis (77% vs 67%, χ2(1)= 11.0, P ≤ 0.001), a lower
proportion of emergency hospital admissions (8% vs 39%, χ2(1)=
111.6, P < 0.001) and a lower proportion of lung cancers with
distant spread (31% vs 59%, χ2(1)= 69.5, P < 0.001).
The third most common pathway (n= 129, 14%) was an
emergency hospital admission without GP-ordered imaging or
lung specialist attendance in the community. Overall, 223 people
(25%) had an emergency hospital admission. People with an
emergency admission had a higher proportion of cancers with
distant spread (67% vs 40%, χ2(1)= 50.8, P < 0.001) and a lower
proportion without comorbidity (69% vs 79%, χ2(1)= 8.6, P <
0.014).
Of the 11% (n= 96) of people with no events of interest
(pathway 5), 15 (16%) saw a general physician or surgeon and 11
(12%) saw a medical or radiation oncologist.
DISCUSSION
The use of community-based health services associated with lung
cancer diagnosis increased rapidly in the 2 months before
diagnosis of NSCLC. The key role that GPs play in the diagnosis
of lung cancer is highlighted by the findings that in the 3 months
to diagnosis 93% attended a GP with 60% of people attending a
GP at least four times and a similar proportion having GP-ordered
thoracic imaging.
The two most common pathways to diagnosis of NSCLC,
accounting for one in three people diagnosed, involved GP and
lung specialists in the community without an emergency hospital
Table 1. Demographic and tumour characteristics of study
participants with non-small cell lung cancer
Characteristic n % (N= 894)
Age at diagnosis, years
45–64 195 21.8
65–79 453 50.7
80+ 246 27.5
Sex
Female 385 43.1
Male 509 56.9
Remoteness of residence
Major cities 477 53.4
Inner regional 314 35.1
Outer regional/remote 103 11.5
Area-based socioeconomic status
Least disadvantaged quintile 137 15.3
Quintile 2 147 16.4
Quintile 3 176 19.7
Quintile 4 256 28.6
Most disadvantaged quintile 178 19.9
Smoking status at enrolmenta
Current smoker 217 24.3
Ex-smoker 524 58.6
Never smoked regularly 150 16.8
Extent of disease at diagnosis
Localised 173 19.4
Regional 204 22.8
Distant 417 46.6
Unknown 100 11.2
Best method of diagnosis
Histopathologically verified 642 71.8
Cytology 169 18.9
Clinical/imaging/biochemistry 83 9.3
Charlson comorbidity score
0 682 76.3
1 130 14.5
≥2 82 9.2
aExcludes people with unknown smoking status
Fig. 1 GP attendances, lung specialist attendances, chest X-rays and
chest CT scans per person in the 15 months before non-small cell
lung cancer diagnosis
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admission, suggesting patients presenting with less severe or
more typical lung cancer symptoms being referred to appropriate
specialists. Nevertheless, fewer than half (45%) of people attended
a lung specialist (respiratory physician or cardiothoracic surgeon)
in the lead-up to diagnosis, which is similar to an earlier NSW
study that reported only 53% of people with lung cancer saw a
respiratory physician at initial presentation.5 Reasons for not
seeing a lung specialist in the community before a diagnosis of
NSCLC could include the sudden onset of severe symptoms
requiring emergency presentation to hospital (e.g. haemoptysis),
referral to a non-lung specialist (e.g. an oncologist or a general
physician), referral to a specialist for the presenting symptoms of
distant metastases (e.g. a neurologist) or an incidental finding of
lung cancer while undergoing investigation for another condition.
An Australian study reported that 23% of people with lung cancer
were diagnosed incidentally.7 Incidental findings will account for
some people diagnosed without GP-ordered imaging or lung
specialist attendance in our study.
There were no substantial differences in patterns of GP and
specialist attendances and chest imaging for people living in outer
regional and remote areas compared with major cities. It appears
that remoteness of residence alone is not a major barrier to seeing
a lung specialist. However, we had no information on lung cancer
MDT membership for the specialists, which may vary by
remoteness. Further research is needed to determine whether
referral to specialists who are active members of lung cancer
MDTs is contributing to higher treatment use and improved
outcomes for people diagnosed with lung cancer in major
cities.3,17
Overall, one quarter of people had an emergency admission for
lung cancer in the lead-up to diagnosis. More than half of these
Table 2. Use of selected health services in the 3 months to diagnosis of non-small cell lung cancer by remoteness of residence
Service Number of services Major cities
(N= 477)
Inner
regional
(N= 314)
Outer
regional/
remote
(N= 103)
Total
(N= 894)
χ2 test
n % n % n % n %
GP attendance 0 35 7.3 17 5.4 7 6.8 59 6.6 χ2(8)= 15.66, P= 0.05
1–3 164 34.4 102 32.5 33 32.0 299 33.4
4–6 162 34.0 133 42.4 49 47.6 344 38.5
7-9 79 16.6 45 14.3 6 5.8 130 14.5
>9 37 7.8 17 5.4 8 7.8 62 6.9
Respiratory physician attendance ≥1 196 41.1 117 37.3 36 35.0 349 39.0 χ2(2)= 1.98, P= 0.37
Cardiothoracic surgeon attendance ≥1 46 9.6 44 14.0 12 11.7 102 11.4 χ2(2)= 3.58, P= 0.17
Medical oncologist attendance ≥1 24 5.0 14 4.5 7 6.8 45 5.0 χ2(2)= 0.89, P= 0.64
Radiation oncologist attendance ≥1 32 6.7 20 6.4 9 8.7 61 6.8 χ2(2)= 0.71, P= 0.70
General physician attendance ≥1 40 8.4 20 6.4 5 4.9 65 7.3 χ2(2)= 2.15, P= 0.34
General surgeon attendance ≥1 31 6.5 27 8.6 9 8.7 67 7.5 χ2(2)= 1.46, P= 0.48
Chest X-ray (outpatient) ≥1 251 52.6 174 55.4 49 47.6 474 53.0 χ2(2)= 1.98, P= 0.37
GP ordereda ≥1 196 41.1 150 47.8 38 36.9 384 43.0 χ2(2)= 5.19, P= 0.07
Specialist ordereda ≥1 74 15.5 33 10.5 12 11.7 119 13.3 χ2(2)= 4.39, P= 0.11
CT scan (outpatient) ≥1 280 58.7 189 60.2 62 60.2 531 59.4 χ2(2)= 0.21, P= 0.90
GP ordereda ≥1 200 41.9 148 47.1 48 46.6 396 44.3 χ2(2)= 2.33, P= 0.31
Specialist ordereda ≥1 93 19.5 45 14.3 15 14.6 153 17.1 χ2(2)= 4.10, P= 0.13
Diagnostic procedures (inpatient/outpatient)b ≥1 222 46.5 145 46.2 48 46.6 415 46.4 χ2(2)= 0.01, P= 0.99
aGP-ordered and specialist-ordered categories are not mutually exclusive: people can have both GP-ordered and specialist-ordered imaging
bBronchoscopy or biopsy
Table 3. Number (%) of chest X-rays and chest CT scans in the
3 months to diagnosis of non-small cell lung cancer
Number of chest X-
rays
Number of chest CT scans Total (column %)
0 1 2
0 262 (29%) 148 (17%) 10 (1%) 420 (47%)
1 94 (11%) 284 (32%) 16 (2%) 394 (44%)
≥2 7 (1%) 65 (7%) 8 (1%) 80 (9%)
Total (row %) 363 (41%) 497 (56%) 34 (4%) 894 (100%)
Table 4. Pathways to diagnosis of non-small cell lung cancer
Rank GP-
ordered
imaging
Lung
specialist
attendance
Elective
admission
Emergency
admission
n % (N= 894)
1 ● ● ● 136 15.2
2 ● ● 132 14.8
3 ● 129 14.4
4 ● 119 13.3
5 96 10.7
6 ● 61 6.8
7 ● ● 61 6.8
8 ● 45 5.0
9 ● ● 43 4.8
10 ● ● 39 4.4
11 ● ● ● 18 2.0
12 ● ● 15 1.7
Note: GP attendance is not included in the pathways because we could not
distinguish attendances for lung-related symptoms from unrelated
attendances
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did not have GP-ordered imaging or a lung specialist attendance.
A higher proportion of people who had emergency hospitalisa-
tions had lung cancer with distant spread compared with those
without an emergency admission, suggesting that symptoms of
late-stage disease are leading to emergency presentations in
some cases. Lung cancer symptoms requiring emergency treat-
ment can occur with little or no prior warning or after a prolonged
period without the patient seeking help for milder symptoms.18
While community awareness programs aim to increase recogni-
tion of symptoms and encourage people to seek medical advice,
there is evidence that people delay seeking medical attention for
reasons including a perceived lack of urgency about symptoms
and stigma associated with lung pathologies if they have been
smokers.19 Another reason for emergency presentation could be
referral to an emergency department, either by a physician or
patient self-referral, as a way to avoid real or perceived waiting
time, financial or distance barriers to accessing a lung specialist or
diagnostic procedures in the community.20,21
It is difficult to compare our pathway results with other studies
because of differences in data sources, methods and health
systems. The proportion of people diagnosed following an
emergency presentation in this study (25%) is lower than the
figure of around one third reported in two other Australian studies
and 39% in a UK study but much higher than the 6% in a Danish
study.9,22–24 Although NSW emergency department data contains
coded diagnostic information, these codes often reflect the
presenting symptoms rather than the underlying diagnosis. The
emergency department codes are assigned by a range of
emergency department staff, whereas diagnoses in the NSW
hospital data are coded by specialist medical coders using the
medical record for each admission. Since people presenting to
emergency departments who are diagnosed with lung cancer are
likely to be admitted, we defined an emergency diagnosis
pathway as one with an emergency hospital admission with a
lung cancer diagnosis in order to avoid capturing people
presenting to emergency departments who do not receive a
definitive diagnosis. Another difference between studies is the
definition of lung specialist. In the absence of information on lung
cancer MDT membership, we included respiratory physicians and
cardiothoracic surgeons, although some studies also include
medical and radiation oncologists as lung specialists.4,5,7
A limitation of the data is that they do not contain presenting
symptoms at GP and specialist attendances or imaging results.
This meant that we were unable to calculate time intervals
between first presentation with lung symptoms and diagnosis or
treatment, assess the appropriateness of the observed pathways
compared to a clinical guideline or standard, or identify people
diagnosed incidentally. Although in our study health service use
was similar across cities and rural areas in the lead-up to diagnosis,
there may be disparity in the time between first presentation with
symptoms and accessing specialist and diagnostic services that
we could not measure. We were unable to identify a diagnostic
procedure for around a third of people with a histopathological
diagnosis, consistent with known under-reporting of diagnostic
procedures in the hospital admission data.25
Smoking prevalence is lower among 45 and Up Study
participants and smoking is the most important lifestyle risk
factor in people presenting with lung cancer.19,26 45 and Up Study
participants diagnosed with lung cancer were less socio-
economically disadvantaged, healthier and less likely to live in
major cities than all NSW residents aged ≥45 years diagnosed with
lung cancer.27 Hospital and emergency department use in the
year prior to lung cancer diagnosis were similar between 45 and
Up Study participants and all NSW residents; however, primary
and outpatient care use could not be assessed.27 Participants of
cohort studies may differ from non-responders in their health
literacy and health-seeking behaviours. This may result in
differences in diagnostic pathways compared with the general
NSW population with lung cancer.
Studies of diagnostic pathways are often based on patient
medical record reviews, surveys or interviews and are restricted to
small geographic areas or a limited number of hospitals.9–11 A
strength of this study is that linkage of health-related records for
45 and Up Study participants enabled the examination of the use
of primary care, outpatient imaging, specialist care and admissions
to hospital in the lead-up to diagnosis of lung cancer for a NSW-
wide sample using data with population-level coverage, which
had previously been a gap in understanding care pathways for
lung cancer.
The Australian Optimal Care Pathway (endorsed in 2015) lays
out expected pathways of initial investigations, referral, diagnosis
and treatment for people presenting with suspected lung cancer
with the aim of promoting best practice care regardless of where
people live or have treatment.28 Our study focussed on GP-
ordered imaging and specialist referral, which are steps laid out in
the Optimal Care Pathway. The optimal pathway for a person with
suspected lung cancer will depend on their presenting signs and
symptoms and may include GP-referred imaging, referral to a
specialist who is part of an MDT and referral of those with massive
haemoptysis or stridor to the emergency department. Our study
period is before the publication of the Optimal Care Pathway but
can provide baseline data on health service use. Some areas in
NSW have implemented localised optimal care pathways using GP
decision aid software that provides management guidelines for
people presenting with respiratory symptoms and referral details
for lung specialists who are MDT members and for rapid access
clinics. This implementation at a local level should assist with
ensuring that people presenting with symptoms receive appro-
priate investigations in a timely way.
This study revealed that more than half of people did not attend
a lung specialist in the diagnostic pathway of NSCLC. A quarter of
people diagnosed presented as emergencies and more than half
of those had no prior evidence of GP or lung specialist
involvement in their diagnostic work-up. This study also highlights
the key role that GPs have in the diagnosis of lung cancer.
Ensuring that GPs have information available to them to initiate
appropriate investigations and referral to specialists who are
members of lung cancer MDTs has the potential to promote best
practice care for people with lung cancer. Further research on
barriers to recognition of lung cancer symptoms and access to
lung specialists is needed from both a patient and physician
perspective.
METHODS
Design and ethical considerations
This descriptive study used linked population-based, health-related data
sets for participants of the 45 and Up Study. Ethical approval was from the
NSW Population and Health Services Research Ethics Committee (HREC/14/
CIPHS/60). The 45 and Up Study was approved by the University of New
South Wales Human Research Ethics Committee.
Study cohort
Our study cohort was selected from participants of the Sax Institute’s 45
and Up Study.29 Participants were randomly sampled from the Department
of Human Services (formerly Medicare Australia) enrolment database,
which is a universal health-care scheme for citizens and permanent
residents. Around 267,000 people joined the 45 and Up Study between
February 2006 and December 2009 (18% participation rate) by completing
a questionnaire and providing signed informed consent to follow-up and
linkage of health records.
Our analysis cohort included people diagnosed with NSCLC (see
Supplementary Table 1 for definition) between enrolment into the 45
and Up Study and 31 December 2012. The focus is on NSCLC because it is
the most common type of lung cancer and less common histology types
can have different presentations and outcomes. People with another
S. Purdie et al.
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cancer case diagnosed between 2000 and 2012, a NSCLC notified by death
certificate only or with an unknown date of diagnosis were excluded.
Data sources
Linkage of 45 and Up Study baseline questionnaire data to population-
based health-related data sets was used to identify cancer diagnoses and
health service use. Cancer case data were obtained from the NSW Cancer
Registry, a statutory registry of all invasive cancer cases (excluding non-
melanoma skin cancer) diagnosed in NSW residents. Hospital admission
records for all NSW public and private hospitals were obtained from the
NSW Admitted Patient Data Collection, which contains coded diagnostic
and procedure information for each admission. GP attendances, specialist
attendances, diagnostic imaging and diagnostic procedures performed in
a community or outpatient setting were identified from Medicare Benefits
Schedule claims data, which is a universal scheme providing subsidised
medical services.
Linkage of the 45 and Up Study cohort to cancer and hospital data was
performed by the Centre for Health Record Linkage (http://www.cherel.org.
au) and to the Medicare Benefits Schedule data by the Sax Institute using a
unique identifier provided to the Department of Human Services.
Cohort characteristics
Demographic and cancer case data were obtained from the NSW Cancer
Registry, including: date of diagnosis, most definitive method of diagnosis,
extent of disease, age at diagnosis, sex, remoteness of residence
(Accessibility/Remoteness Index of Australia [ARIA+]), and area-based
socioeconomic disadvantage (Index of Relative Socioeconomic Disadvan-
tage).30,31 Smoking status was obtained from the 45 and Up Study baseline
questionnaire. The Charlson comorbidity score, excluding metastatic
cancer, was calculated using hospital admissions in the 5 years prior to
diagnosis.32
Use of health services in the lead-up to diagnosis
We quantified the use of GP attendances, specialist attendances, chest X-
rays and chest CT scans in a community setting (outside a hospital
admission), diagnostic procedures (bronchoscopy or biopsy) in an
outpatient or inpatient setting and hospital admissions related to the
diagnosis of lung cancer in the 15 months prior to diagnosis of NSCLC (see
Supplementary Table 1 for definitions). We calculated the proportion of
people using each service in the lead-up to diagnosis, which we defined as
the 3 months (91 days) up to and including the date of diagnosis, based on
the study data and the findings of other studies.12,21 The date of diagnosis
on the NSWCR during the study period is the date of histological or
cytological confirmation for the majority of cases or, for those with a
clinical diagnosis, the date of first hospital admission or outpatient
consultation.
Pathways to diagnosis
We defined pathways to diagnosis by the presence or absence in the lead-
up to diagnosis of:
● GP-ordered chest imaging (X-ray or CT scan);
● lung specialist (respiratory physician or cardiothoracic surgeon)
attendance in a community/outpatient setting;
● hospital admission with a lung cancer indication, by urgency of first
admission (planned or emergency).
These events indicate the involvement of GPs, lung specialists and
hospitals in the diagnostic work-up. GP attendances were not included in
the diagnosis pathway analyses because we could not distinguish lung
cancer-related attendances from attendances for unrelated conditions.
Statistical analysis
We used Pearson’s chi-square tests to assess associations between
remoteness of residence and use of health services, and between
outcomes of interest (seeing a lung specialist and emergency presentation)
and patient characteristics or other events on the diagnostic pathway.
Two-sided P values are reported. Analyses were performed using SAS
Enterprise Guide v6.1.
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